Recombinant Mouse Anti-CHIKV VLP Antibody (CHK152) (CAT#: PABL-043)

Figure 1 Profile of neutralizing MAbs against CHIKV.

CHK-152 was mixed with CHIKV-LR (East, Central and South African genotype), CHIKV-RSUI (Asian genotype), or CHIKV IbH35 (West Africangenotype) for one hour at 37°C and Vero or NIH 3T3 cells were infected. Neutralization was determined by FFU assay.

Pal, P., Dowd, K. A., Brien, J. D., Edeling, M. A., Gorlatov, S., Johnson, S., ... & Smit, J. M. (2013). Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS pathogens, 9(4).

Figure 2 Efficacy of anti-CHIKV MAb prophylaxis.

Four week-old female WT C57BL/6 mice were sham-treated or administered 100 mg of CHK-152 via an i.p. route. 24 hours later, mice were infected with 100 PFU of CHIKV-SL 15649 and at day 10, virus-inducedpathology in the foot and ankle joint was assessed. Shown are representative images after hematoxylin and eosinstaining from at least 3 mice per group at 100× magnification. Yellow and green arrows indicate regions of inflammation or normal joints,respectively.

Pal, P., Dowd, K. A., Brien, J. D., Edeling, M. A., Gorlatov, S., Johnson, S., ... & Smit, J. M. (2013). Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS pathogens, 9(4).

Figure 3 Pre- and post-attachment inhibition assays.

Vero cells were pre-chilled to 4°C and 100 FFU of CHIKV-LR was added to each well for one hour. After extensive washing at 4°C, the indicated MAbs were added for one hour at 4°C, andthen the FRNT protocol was completed (black lines,Post). In comparison, a standard pre-incubation FRNT with all steps performed at 4°C is shown forreference. Virus and MAb are incubated together for one hour at 4°C, prior to addition to cells (red lines, Pre). Data shown are representative of threeexperiments performed in duplicate with error bars representing standard deviation.

Pal, P., Dowd, K. A., Brien, J. D., Edeling, M. A., Gorlatov, S., Johnson, S., ... & Smit, J. M. (2013). Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS pathogens, 9(4).

Figure 4 The effector functions of CHK-152 contribute to protectionin vivo.

Comparison of neutralizing activity of murine CHK-152, ch-CHK-152, and ch-CHK-152 N297Q, as measured by FRNTon Vero cells.

Pal, P., Dowd, K. A., Brien, J. D., Edeling, M. A., Gorlatov, S., Johnson, S., ... & Smit, J. M. (2013). Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS pathogens, 9(4).